Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.

[1]  F. Cardoso,et al.  Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Yeon-Hee Park,et al.  Treating HR+/HER2− breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression , 2019, Breast Cancer Research and Treatment.

[3]  C. Caldas,et al.  6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial , 2019, The Lancet.

[4]  Sung-Bae Kim,et al.  Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer. , 2019, Future oncology.

[5]  Chen Hu,et al.  Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. , 2019, The Lancet. Oncology.

[6]  Junjie Li,et al.  Abstract P6-17-17: Pertuzumab, trastuzumab, and docetaxel for HER2-positive early or locally advanced breast cancer in the neoadjuvant setting: Efficacy and safety analysis of a randomized phase III study in Asian patients (PEONY) , 2019, Poster Session Abstracts.

[7]  S. Lai,et al.  Correlation of the tamoxifen use with the increased risk of deep vein thrombosis and pulmonary embolism in elderly women with breast cancer , 2018, Medicine.

[8]  Joon Jeong,et al.  A phase II study investigating the acute toxicity of targeted intraoperative radiotherapy as tumor-bed boost plus whole breast irradiation after breast-conserving surgery in Korean patients , 2018, Breast Cancer Research and Treatment.

[9]  M. Calaguas,et al.  A Prospective International Study on Safety and Efficacy of Hypofractionated Radiation Therapy for Post-Operative Breast Cancer Patients in Asian Countries , 2018, International Journal of Radiation Oncology*Biology*Physics.

[10]  C. Yip,et al.  Breast‐conserving surgery versus mastectomy in young women with breast cancer in Asian settings , 2018, BJS open.

[11]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[12]  Joon Jeong,et al.  Comparative Study between Sentinel Lymph Node Biopsy and Axillary Dissection in Patients with One or Two Lymph Node Metastases , 2018, Journal of breast cancer.

[13]  W. Han,et al.  Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: The ASTRRA study. , 2018 .

[14]  D. Wallwiener,et al.  Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  San-Gang Wu,et al.  Comparable Survival between Additional Radiotherapy and Local Surgery in Occult Breast Cancer after Axillary Lymph Node Dissection: A Population-based Analysis , 2017, Journal of Cancer.

[16]  J Bogaerts,et al.  ESMO-Magnitude of Clinical Benefit Scale version 1.1 , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  P. Poortmans,et al.  Less is more. Breast conservation might be even better than mastectomy in early breast cancer patients. , 2017, Breast.

[18]  A. Giuliano,et al.  Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial , 2017, JAMA.

[19]  H. Kim,et al.  Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations. , 2017, AJR. American journal of roentgenology.

[20]  Marion Procter,et al.  Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer , 2017, The New England journal of medicine.

[21]  Sung-Bae Kim,et al.  Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy , 2017, The New England journal of medicine.

[22]  L. Koppert,et al.  Breast conserving therapy and mastectomy revisited: Breast cancer‐specific survival and the influence of prognostic factors in 129,692 patients , 2017, International journal of cancer.

[23]  G. H. de Bock,et al.  Breast-conserving therapy versus mastectomy in T1-2N2 stage breast cancer: a population-based study on 10-year overall, relative, and distant metastasis-free survival in 3071 patients , 2016, Breast Cancer Research and Treatment.

[24]  J. Lee,et al.  Characterization of Korean Male Breast Cancer Using an Online Nationwide Breast-Cancer Database , 2016, Medicine.

[25]  T. Endo,et al.  Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial , 2016, The Lancet.

[26]  S. Barni,et al.  Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial , 2015, The Lancet.

[27]  J. Bogaerts,et al.  Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. , 2014, The Lancet. Oncology.

[28]  A. Giobbie-Hurder,et al.  Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. , 2014, The New England journal of medicine.

[29]  Sun Young Min,et al.  The Basic Facts of Korean Breast Cancer in 2011: Results of a Nationwide Survey and Breast Cancer Registry Database , 2014, Journal of breast cancer.

[30]  H. Verkooijen,et al.  Spectrum of very early breast cancer in a setting without organised screening , 2014, British Journal of Cancer.

[31]  R. Laing,et al.  Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial. , 2014, The Lancet. Oncology.

[32]  E. Chuwa,et al.  Young breast cancer in a specialised breast unit in Singapore: clinical, radiological and pathological factors. , 2014, Annals of the Academy of Medicine, Singapore.

[33]  Jianjun He,et al.  A 10-year (1999 ~ 2008) retrospective multi-center study of breast cancer surgical management in various geographic areas of China. , 2013, Breast.

[34]  J. Lee,et al.  Association between BRCA Mutation Status, Pathological Findings, and Magnetic Resonance Imaging Features in Patients with Breast Cancer at Risk for the Mutation , 2013, Journal of breast cancer.

[35]  J. Boyages,et al.  The Effects of Postmastectomy Adjuvant Radiotherapy on Immediate Two-Stage Prosthetic Breast Reconstruction: A Systematic Review , 2013, Plastic and reconstructive surgery.

[36]  Alan I Glaser,et al.  Survival after lumpectomy and mastectomy for early stage invasive breast cancer: The effect of age and hormone receptor status , 2013, Cancer.

[37]  P. Neven,et al.  Is the sentinel lymph node biopsy more sensitive for the identification of positive lymph nodes in breast cancer than the axillary lymph node dissection? , 2013, SpringerPlus.

[38]  B. Fowble,et al.  Survival after lumpectomy and mastectomy for early stage invasive breast cancer , 2013, Cancer.

[39]  M. R. del Turco,et al.  Mastectomy trends for early-stage breast cancer: a report from the EUSOMA multi-institutional European database. , 2012, European journal of cancer.

[40]  S. Nag,et al.  Challenges and opportunities in the design and implementation of breast cancer clinical trials in developing countries , 2012 .

[41]  Yuanyuan Zhang,et al.  Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials. , 2012, Breast.

[42]  A. Musolino,et al.  Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  R. Gelber,et al.  Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial , 2012, The Lancet.

[44]  R. Greil,et al.  Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. , 2011, The Lancet. Oncology.

[45]  S. Im,et al.  Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[46]  A. Giuliano,et al.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.

[47]  Talia K. Ben-Jacob,et al.  Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: The American College of Surgeons Oncology Group Z0011 Randomized Trial , 2010, Annals of surgery.

[48]  A. Derossis,et al.  Is Breast Cancer the Same Disease in Asian and Western Countries? , 2010, World Journal of Surgery.

[49]  D. Palli,et al.  Male breast cancer. , 2010, Critical reviews in oncology/hematology.

[50]  R. Greil,et al.  Endocrine therapy plus zoledronic acid in premenopausal breast cancer. , 2009, The New England journal of medicine.

[51]  C. Yip,et al.  Breast cancer in Sabah, Malaysia: a two year prospective study. , 2007, Asian Pacific journal of cancer prevention : APJCP.

[52]  Vivek Aggarwal,et al.  Spectrum of Breast Cancer in Asian Women , 2007, World journal of surgery.

[53]  R. Gelber,et al.  Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[55]  Chiun Hsu,et al.  Significant Difference in the Trends of Female Breast Cancer Incidence Between Taiwanese and Caucasian Americans: Implications from Age-Period-Cohort Analysis , 2005, Cancer Epidemiology Biomarkers & Prevention.

[56]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[57]  Noriaki Ohuchi,et al.  The increase of female breast cancer incidence in Japan: Emergence of birth cohort effect , 2004, International journal of cancer.

[58]  Ming-Feng Hou,et al.  Comparison of breast mammography, sonography and physical examination for screening women at high risk of breast cancer in taiwan. , 2002, Ultrasound in medicine & biology.

[59]  C. Dykewicz.  Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  B. Mohanti,et al.  Attitudes and treatment outcome of breast conservation therapy for stage I & II breast cancer using peroperative iridium-192 implant boost to the tumour bed. , 2001, Australasian radiology.

[61]  J. Tabernero,et al.  Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[62]  D. Penson,et al.  Nationwide trends in mastectomy for early-stage breast cancer. , 2015, JAMA surgery.

[63]  E. Rutgers,et al.  Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  Giulia Bianchi,et al.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.